Lv2
180 积分 2024-09-23 加入
Thyroid hormones as a disease modifier and therapeutic target in nonalcoholic steatohepatitis
14天前
已完结
Health-Related quality of life (HRQL) assessments in a 52-Week, Double-Blind, randomized, Placebo-Controlled phase 3 study of resmetirom (MGL-3196) in patients with metabolic dysfunction associated steatohepatitis (MASH) and fibrosis
1个月前
已完结
Natural history and progression of metabolic dysfunction-associated steatotic liver disease
1个月前
已完结
皖公网安备34019202002308
